EGFR and non-small cell lung carcinoma: Moreover, our study further demonstrated that the addition of bevacizumab to EGFR-TKI was more effective than to chemotherapy in EGFR mutant NSCLC patients who developed EGFR-TKI acquired resistance and presented as MPE.